Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 16th Jan 2020 12:58
(Sharecast News) - Diageo: Jefferies downgrades to hold with a target price of 3,600p

Auto Trader: Credit Suisse reiterates underperform with a target price of 480p.

Coca-Cola: Deutsche Bank reiterates buy with a target price of 3,100p.

AstraZeneca: Barclays reiterates overweight with a target price of 8,500p.

IQE: Barclays downgrades to equal weight with a target price of 55p.

Spirent Communications: Barclays downgrades to underweight with a target price of 190p.

Gamma Communications: Barclays reiterates overweight with a target price of 1,350p.

GlaxoSmithKline: Credit Suisse reiterates neutral with a target price of 1,860p.

4imprint Group: Peel Hunt downgrades to hold with a target price of 3,250p.

Brown N Group: Peel Hunt downgrades to hold with a target price of 150p.

Tullow Oil: Barclays downgrades to equal weight with a target price of 75p.

Electrocomponents: JP Morgan upgrades to overweight with a target price of 774p.

BAE Systems: JP Morgan upgrades to overweight with a target price of 715p.

Vodafone: Goldman Sachs initiates at buy with a target price of 190p. Tullow Oil Astrazeneca 4Imprint Gamma Communications Auto Trader BAE Systems Diageo Vodafone Coca-Cola HBC IQE Glaxosmithkline

Shares in this article

Related News

London's FTSE 100 muted as Iran escalates strikes on US bases
1 hour ago

London's FTSE 100 muted as Iran escalates strikes on US bases

* FTSE 100 up 0.03%, FTSE 250 down 0.1%

Market News Plus500 + 4 more shares
WINNERS & LOSERS: Vodafone extends rally; ME Group sales back on track
1 hour ago

WINNERS & LOSERS: Vodafone extends rally; ME Group sales back on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday.

Risers and Fallers Vodafone + 19 more shares
GSK posts encouraging data for bowel cancer treatment Jemperli
2 hours ago

GSK posts encouraging data for bowel cancer treatment Jemperli

(Alliance News) - GSK PLC on Monday reported encouraging trial data for its cancer treatment Jemperli, also known as dostarlimab.